Skip to main content
    N

    Novocure Ltd (NVCR)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $11.30
    -0.53 (-4.48%)

    Market Cap: $1.38B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Novocure Ltd (NVCR) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Novocure (NVCR) trades at 1.8x sales and 3.8x book value. Its P/S of 1.8x is below its 5-year median of 3.4x. Its forward P/E is 909.1x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E909.1x
    Price to sales1.8x
    Price to book3.8x
    PEGN/A
    FCF yield-1.9%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 86.2% below 13.0x and its P/B is 77.1% below 16.6x.

    MultipleCurrent5-year median10-year median
    P/S1.8x3.4x13.0x
    P/B3.8x5.7x16.6x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/S ranged from 2.2x in 2025 to 36.2x in 2020. 2025 was the lowest of those years.

    Year endPriceP/EP/SP/B
    2025$12.93N/A2.2x4.2x
    2024$29.80N/A5.3x8.9x
    2023$14.93N/A3.1x4.4x
    2022$73.35N/A14.3x17.5x
    2021$75.08N/A14.5x19.0x
    2020$173.04910.7x36.2x40.2x
    2019$84.27N/A23.9x41.8x
    2018$33.48N/A12.4x27.8x
    2017$20.20N/A10.1x15.9x
    2016$7.85N/A8.1x4.8x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About NVCR

    What is NVCR's forward P/E ratio?

    Novocure has a forward P/E ratio of 909.1x.

    Is NVCR stock overvalued?

    GNG's valuation label for NVCR is Undervalued.

    What is NVCR's price to sales ratio?

    Novocure has a price to sales ratio of 1.8x.